Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A

References

• RosnerFHemophilia in classic Rabbinic textsJ Hist Med Allied Sci1994492402508034967
   PubMed Web of Science ®Google Scholar
• PatekAJHemophilia II: Some properties of a substance obtained from normal plasma effective in accelerating the clotting of hemophilic bloodJ Clin Invest19371611312416694450
   PubMedGoogle Scholar
• GoodeveACPeakeIRThe molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor developmentSemin Thromb Hemost200329233012640561
   PubMed Web of Science ®Google Scholar
• IkkalaEHeilskeTMyllylaGChanges in the life expectancy of patients with severe haemophilia A in Finland in 1930–1979Br J Haematol1982527126810913
   PubMed Web of Science ®Google Scholar
• ChorbaTLHolmanRCStrineTWChanges in longevity and causes of death among persons with hemophilia AAm J Hematol1994451121218141117
   PubMed Web of Science ®Google Scholar
• Meija-CarvajalCCzapekEEValentinoLALife expectancy in hemophilia outcomeJ Thromb Haemost2006450750916460431
   PubMed Web of Science ®Google Scholar
• Donadel-ClaeyssensSCurrent coordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management)Haemophilia20061212412716476085
   PubMed Web of Science ®Google Scholar
• PoolJGHershgoldEJPappenhagenARHigh-potency anti-haemophilic factor concentrate prepared from cryoglobulin precipitateNature196420331214201780
   PubMed Web of Science ®Google Scholar
• RotblatFGoodallAHO’BRienDPMonoclonal antibodies to human procoagulant factor VIIIJ Lab Clin Med19831017367466403638
   PubMed Web of Science ®Google Scholar
• GitschierJWoodWIGoralkaTMCharacterization of the human factor VIII geneNature19843123263306438525
   PubMed Web of Science ®Google Scholar
• TooleJJKnopfJLWozneyJMMolecular cloning of a cDNA encoding human antihemophilic factorNature19843123423476438528
   PubMed Web of Science ®Google Scholar
• WhiteGCMcMillanCWKingdonHSUse of recombinant antihemophilic factor in the treatment of two patients with classic hemophiliaN Engl J Med19893231661702492083
   PubMed Web of Science ®Google Scholar
• SchwartzRSAbilgaardCFAledortLMHuman recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophiliaN Engl J Med1990323180018052123300
   PubMed Web of Science ®Google Scholar
• MittererAKaliwodaMKumarHPMRecombinant FVIII manufactured without the use of animal/human derived substances (rAHF-PFM). [Abstract]Blood200210092b
   Web of Science ®Google Scholar
• AbshireTCBrackmannHHScharrerISucrose formulated recombinant antihemophilia factor FVIII is safe and efficacious for treatment of hemophilia A in home therapyThromb Haemost20008381181610896230
   PubMed Web of Science ®Google Scholar
• TarantinoMDNavaleLMBrayGLClinical evaluation of a new generation recombinant FVIII, plasma/albumin-free method (rAHF-PFM). [Abstract]Blood2002100493a
   Web of Science ®Google Scholar
• LusherJMArkinSAbildgaardCFRecombinant factor VIII for the treatment of previously untreated patients with hemophilia AN Engl J Med19933284534598421474
   PubMed Web of Science ®Google Scholar
• LusherJMRecombinant clotting factors. A review of current clinical statusBio-Drugs200013289298
   Google Scholar
• BrayGLGompertsEDCourterSA multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia ABlood199483242824358167332
   PubMed Web of Science ®Google Scholar
• WhiteGCCourterSBrayGLA multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia AThromb Haemost1997776606679134639
   PubMed Web of Science ®Google Scholar
• LusherJMLeeCAKesslerCMThe safety and efficacy of B domain deleted recombinant factor VIII concentrate in patients with severe hemophilia AHaemophilia20039384912558777
   PubMed Web of Science ®Google Scholar
• AhnstromJBerntorpELindvallKA 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophiliaHaemophilia20041068969715569163
   PubMed Web of Science ®Google Scholar
• ValentinoLAHakobyanNKazarianTExperimental haemophilic synovitis: rationale and development of a murine model of human factor VIII deficiencyHaemophilia20041028028715086328
   PubMed Web of Science ®Google Scholar
• RoosendaalGLafeberFPBlood-induced joint damage in hemophiliaSemin Thromb Hemost200329374212640563
   PubMed Web of Science ®Google Scholar
• WenFQJabbarAAChenYXC-myc proto-oncogene expression in hemophilic synovitis: in vitro studies of the effects of iron and ceramideBlood200210091291612130502
   PubMed Web of Science ®Google Scholar
• PetterssonHAhlbergANilssonIMA radiologic classification of hemophilia arthropathyClin Orthop19801491531597408294
   PubMed Web of Science ®Google Scholar
• AbdelrazikNRedaMEl-ZinyMEvaluation of bone mineral density in children with hemophilia: Mansoura University children hospital (MUCH) experience, Mansoura, EgyptHematology20071243143717852436
   PubMed Web of Science ®Google Scholar
• AledortLMHaschmeyerRHPetterssonHA longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study GroupJ Intern Med19942363913997931042
   PubMed Web of Science ®Google Scholar
• FisherKvan der BoJGMauser-BunschotenEPThe effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophiliaBlood2002992337234111895765
   PubMed Web of Science ®Google Scholar
• FisherKvan HoutBAvan der BomJGAssociation between joint bleeds and Pettersson scores in severe haemophiliaActa Radiol20024352853212423465
   PubMed Web of Science ®Google Scholar
• NilssonIMBlombackMAhlbergAOur experience in Sweden with prophylaxis on haemophiliaBibl Haematol1970341111245436339
   PubMedGoogle Scholar
• Van CreveldSProphylaxis of joint hemorrhages in hemophiliaActa Haematol1969412062144979341
   PubMed Web of Science ®Google Scholar
• KasperCKDietrichSLRapaportSIHemophilia prophylaxis with factor VIII concentrateArch Intern Med1970125100410094951928
   PubMedGoogle Scholar
• Manco-JohnsonMJNussRGeraghtySResults of secondary prophylaxis in children with severe hemophiliaAm J Hematol1994471131178092125
   PubMed Web of Science ®Google Scholar
• KreuzWEscuriola-EttingshausenCFunkMWhen should prophylactic treatment in patients with haemophilia A and B start? The German experienceHaemophilia199844134179873763
   PubMed Web of Science ®Google Scholar
• NilssonIMBerntorpELofqvistTTwenty-five years’ experience of prophylactic treatment in severe haemophilia A and BJ Intern Med199223225321640190
   PubMed Web of Science ®Google Scholar
• LofquistTNilssonIMBerntorpEHaemophilia prophylaxis in young patients-a long-term follow-upJ Intern Med19972413954009183307
   PubMed Web of Science ®Google Scholar
• AstermarkJPetriniPTengbornLPrimary prophylaxis in severe haemophilia should be started at an early age but can be individualizedBr J Haematol19991051109111310554828
   PubMed Web of Science ®Google Scholar
• CarlssonMBerntorpEBjorkmanSPharmacokinetic dosing in prophylactic treatment of hemophilia AEur J Haematol1993512472528243614
   PubMed Web of Science ®Google Scholar
• FisherKAstermarkJvan der BomJGProphylactic treatment for severe hemophilia: comparison of an intermediate-dose to high-dose regimenHaemophilia2002875376012410643
   PubMed Web of Science ®Google Scholar
• BlanchetteVRivardGIsraelsSMusculoskeletal results from the Canadian Hemophilia Dose-Escalation Prophylaxis Trial. [Abstract]Blood200310252a
   Web of Science ®Google Scholar
• FeldmanBMPaiMRivardGETailored prophylaxis in severe hemophilia: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis StudyJ Thromb Haemost200641228123616706965
   PubMed Web of Science ®Google Scholar
• BerntorpEBoulyjenkovVBrettlerDModern treatment of haemophiliaBull World Health Organ1995736917018846496
   PubMed Web of Science ®Google Scholar
• Medical and Scientific Advisory CouncilMASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding)New York, NYNational Hemophilia Foundation2006 MASAC Recommendation 170.
   Google Scholar
• SrivastavaAGiangrandePPoonMCGuidelines for the Management of HemophiliaAvailable at: http://www/wfh.org/2/docs/Publications/Diagnosis_and_Treatment/Guidelines_Mng_Hemophilia.pdf Montreal, QuebecWorld Federation of Hemophilia2005
   Google Scholar
• SchobessRKurnikKFriedrichsFEffects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia AThromb Haemost200899717618217137
   PubMed Web of Science ®Google Scholar
• den UijlIEMFischerKIncluding the life-time cumulative number of joint bleeds in the definition of primary prophylaxis. [letter]Thromb Haemost20089996518449430
   PubMed Web of Science ®Google Scholar
• PlugIvan der BomJGPetersMThirty years of hemophilia treatment in the Netherlands, 1972–2001Blood20041043494350015308570
   PubMed Web of Science ®Google Scholar
• KhairKLawrenceKButlerRAssessment of treatment practice patterns for severe hemophilia A: a global nurse perspectiveActa Haematol200811911512318367832
   PubMed Web of Science ®Google Scholar
• BissTTChanAKBlanchetteVSThe use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis surveyHaemophilia20081492393018637844
   PubMed Web of Science ®Google Scholar
• TakiMShirataACurrent situation of regular replacement therapy (prophylaxis) for haemophilia in JapanHaemophilia200915788218700841
   PubMed Web of Science ®Google Scholar
• ButlerRBMcClureWWulffKPractice patterns in haemophilia A therapy-a survey of treatment centers in the United StatesHaemophilia2003954955414511293
   PubMed Web of Science ®Google Scholar
• GeraghtySDunkleyTHarringtonCPractice patterns in haemophilia A therapy-global progress towards optimal careHaemophilia200612758116409179
   PubMed Web of Science ®Google Scholar
• BlanchetteVSMcCreadyMAchonuCA survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centersHaemophilia20039Suppl192612709033
   PubMedGoogle Scholar
• Van DijkKFisherKvan der BomJGCan long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the NetherlandsBr J Haematol200513010711215982352
   PubMed Web of Science ®Google Scholar
• RichardsMAltisentCBatorovaAShould prophylaxis be used in adolescent and adult patients with severe haemophilia? A European survey of practice and outcome dataHaemophilia20071347347917880432
   PubMed Web of Science ®Google Scholar
• TagliaferriAFranchiniMCoppolaAEffects of secondary prophylaxis started in adolescent and adult haemophiliacsHaemophilia20081494595118540895
   PubMed Web of Science ®Google Scholar
• FisherKValentinoLLjungRProphylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitorsHaemophilia200814Suppl 319620118510542
   PubMedGoogle Scholar
• WalshCEAdult Prophylaxis Study GroupProphylaxis for adults with severe haemophilia: a compelling need for evidence-based guidelines. [letter]Haemophilia20081438538618201188
   PubMed Web of Science ®Google Scholar
• AronstamAArblasterPGRainsfordSGProphylaxis in haemophilia: a double-blind controlled trialBr J Haematol1976338190773416
   PubMed Web of Science ®Google Scholar
• AronstamAKirkPJMcHardyJTwice weekly prophylactic therapy in haemophilia AJ Clin Pathol1977306567320230
   PubMed Web of Science ®Google Scholar
• CarlssonMBerntorpEBjorkmanSImproved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia AHaemophilia1997396101
   PubMed Web of Science ®Google Scholar
• MorfiniMMannucciPMMarianiGEvaluation of prophylactic replacement therapy in haemophilia BScand J Haematol19761641471251139
   PubMedGoogle Scholar
• GringeryAA 10-year, randomized, clinical trial on prophylaxis vs on-demand treatment in children with haemophilia A: the E.S.P.R.I.T. study. [Abstract]Haemophilia200814Suppl 299
   Google Scholar
• Manco-JohnsonMAbshireTShapiroAProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophiliaN Engl J Med200735753554417687129
   PubMed Web of Science ®Google Scholar
• YeeTTWilliamsMDHillFGAbsence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII productThromb Haemost199778102710299308748
   PubMed Web of Science ®Google Scholar
• EhrenforthSKreuzWScharrerIIncidence of development of factor VIII and factor IX inhibitors in haemophiliacsLancet19923395945981347102
   PubMed Web of Science ®Google Scholar
• GiangrandePLFfor the Kogenate Bayer Study GroupSafety and efficacy of Kogenate Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs)Haemophilia20028Suppl 2192211966848
   PubMed Web of Science ®Google Scholar
• WightJPaisleySThe epidemiology of inhibitors in haemophilia A: a systemic reviewHaemophilia2003941843512828678
   PubMed Web of Science ®Google Scholar
• LusherJAbilgaardCArkinSHuman recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigationJ Thromb Haemost20042457458315102011
   PubMedGoogle Scholar
• van der BomJGMauser-BunschotenEPFischerKAge at first treatment and immune tolerance to factor VIII in severe hemophiliaThromb Haemost20038947547912624630
   PubMed Web of Science ®Google Scholar
• LorenzoJILopezAAltisentCIncidence of factor VIII inhibitors in severe hemophilia: the importance of patient ageBr J Haematol200111360060311380444
   PubMed Web of Science ®Google Scholar
• SantagostinoEMancusoMERocinoAEnvironmental risk factors for inhibitor development in children with haemophilia A: a case-control studyBr J Haematol200513042242716042693
   PubMed Web of Science ®Google Scholar
• GouwSCvan der BomJGMarijke van den BergHTreatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort studyBlood20071094648465417289808
   PubMed Web of Science ®Google Scholar
• ScharrerIEhrlichHJLack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIIIHaemophilia2001734634811442637
   PubMed Web of Science ®Google Scholar
• GilesARRivardGETeitelJSurveillance for factor VIII inhibitor development in the Canadian hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapyTransfus Sci19981913914810187039
   PubMedGoogle Scholar
• MancusoMEGracaLAuerswaldGHaemophilia care in children – benefits of early prophylaxis for inhibitor preventionHaemophilia200915Suppl 181419125935
   PubMedGoogle Scholar
• RisebroughNOhPBlanchetteVCost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on demand therapy in young children with severe haemophilia AHaemophilia20081474375218422610
   PubMed Web of Science ®Google Scholar
• Steen CarlssonKHojgardSGlomsteinAOn-demand vs prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcomeHaemophilia2003955556614511294
   PubMed Web of Science ®Google Scholar
• KhawajiMAkessonKBerntorpELong-term prophylaxis in severe haemophilia seems to preserve bone mineral densityHaemophilia20091526126619149852
   PubMed Web of Science ®Google Scholar
• NicholsonABergerKBohnRRecommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal group’s consensus statement on behalf of the Economics Expert Working Group for The International Prophylaxis Study GroupHaemophilia20081412713218005148
   PubMed Web of Science ®Google Scholar
• BlanchetteVSShapiroADLiesnerRJPlasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patientsJ Thromb Haemost200861319132618503631
   PubMed Web of Science ®Google Scholar
• PollmannHExternestDGanserAEfficacy, safety, and tolerability of recombinant factor VIII (REFACT) in patients with hemophilia A: interim data from a post marketing surveillance study in Germany and AustriaHaemophilia20071313114317286765
   PubMed Web of Science ®Google Scholar
• ShapiroAGruppoRPabingerIIntegrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia AExpert Opin Biol Ther2009927328319216617
   PubMed Web of Science ®Google Scholar
• CollinsPWBlanchetteVSFischerKBreak-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia AJ Thromb Haemost2009741342019143924
   PubMed Web of Science ®Google Scholar